Siamab Therapeutics Presents New Data at AACR’s Ovarian Cancer Conference Demonstrating its Anti-STn Antibody Therapeutics Inhibit Tumor Growth in Ovarian Cancer Models
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced the presentation of new preclinical data for its novel anti-Sialyl-Tn (STn) antibodies and antibody drug conjugates (ADCs) that show inhibition of tumor progression in in vivo and in vitro patient derived xenograft (PDX) ovarian cancer models with complete regression in some treatment arms. Read more >>